Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|January 30, 2012
Bipolar Disorder and Obesity: What's the Connection?
Comorbid obesity and bipolar disorder together affect the executive functioning of patients.
Advertisement
In a
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Don't miss out on these CME articles! Test your knowledge here.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5